| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NCL |
| Uniprot No | P19338 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-482aa |
| 氨基酸序列 | VKLAKAGKNQGDPKKMAPPPKEVEEDSEDEEMSEDEEDDSSGEEVVIPQK KGKKAAATSAKKVVVSPTKKVAVATPAKKAAVTPGKKAAATPAKKTVTPA KAVTTPGKKGATPGKALVATPGKKGAAIPAKGAKNGKNAKKEDSDEEEDD DSEEDEEDDEDEDEDEDEIEPAAMKAAAAAPASEDEDDEDDEDDEDDDDD EEDDSEEEAMETTPAKGKKAAKVVPVKAKNVAEDEDEEEDDEDEDDDDDE DDEDDDDEDDEEEEEEEEEEPVKEAPGKRKKEMAKQKAAPEAKKQKVEGT EPTTAFNLFVGNLNFNKSAPELKTGISDVFAKNDLAVVDVRIGMTRKFGY VDFESAEDLEKALELTGLKVFGNEIKLEKPKGKDSKKERDARTLLAKNLP YKVTQDELKEVFEDAAEIRLVSKDGKSKGIAYIEFKTEADAEKTFEEKQG TEIDGRSISLYYTGEKGQNQDYRGGKNSTWS |
| 预测分子量 | 54 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及NCL(核仁素)重组蛋白研究的文献示例(文献信息为模拟概括，非真实文献)：
---
1. **标题**: "Recombinant Nucleolin as a Potential Therapeutic Agent in Breast Cancer"
**作者**: Zhang et al. (2020)
**摘要**: 研究利用大肠杆菌表达系统成功制备重组人源NCL蛋白，并通过体外实验验证其与G-四链体DNA结合的能力，证明重组NCL可抑制乳腺癌细胞增殖并诱导凋亡。
---
2. **标题**: "Structural Characterization of Recombinant Nucleolin and Its Interaction with Aptamers"
**作者**: Lee & Kim (2018)
**摘要**: 通过X射线晶体学解析重组NCL的N端结构域，揭示其与肿瘤靶向核酸适体的特异性结合机制，为基于NCL的靶向药物设计提供结构基础。
---
3. **标题**: "A Novel Purification Strategy for High-Yield Nucleolin Recombinant Protein in Insect Cells"
**作者**: Gupta et al. (2021)
**摘要**: 开发了一种基于杆状病毒-昆虫细胞表达系统的NCL重组蛋白高效纯化方法，优化后的工艺使蛋白产量提升3倍，并保留完整生物学活性。
---
4. **标题**: "Engineered Nucleolin-Targeted Nanoparticles for siRNA Delivery in Glioblastoma"
**作者**: Rossi et al. (2019)
**摘要**: 利用重组NCL修饰的纳米颗粒靶向胶质母细胞瘤表面过表达的核仁素受体，显著提高siRNA的递送效率并抑制肿瘤生长。
---
注：以上文献为示例性内容，实际研究中建议通过PubMed或Web of Science检索关键词(如"recombinant nucleolin"、"NCL protein expression")获取真实文献。
**Background of NCL Recombinant Protein**
Nucleolin (NCL), a multifunctional phosphoprotein, is predominantly localized in the nucleolus but also shuttles to the cytoplasm and cell membrane. It plays critical roles in ribosomal RNA (rRNA) processing, chromatin remodeling, cell proliferation, and apoptosis. Structurally, NCL contains three conserved domains: an N-terminal acidic region rich in glutamate and aspartate residues, central RNA-binding domains (RNA recognition motifs, RRMs), and a C-terminal arginine/glycine-rich (RGG) domain. These domains enable its involvement in DNA/RNA interactions, protein complex assembly, and cellular signaling.
The recombinant form of NCL is engineered using genetic cloning techniques, often expressed in *E. coli* or eukaryotic systems to ensure proper folding and post-translational modifications. Recombinant NCL retains the functional domains of the native protein, making it valuable for studying its biological mechanisms, such as its role in cancer progression (e.g., promoting angiogenesis and tumor growth) or viral infections (e.g., serving as a receptor for pathogens like HIV and influenza).
Research applications of NCL recombinant protein include *in vitro* binding assays, structural studies, and drug discovery. Its involvement in stress response pathways and regulation of microRNA processing further highlights its therapeutic potential. Additionally, NCL's interaction with extracellular ligands, such as growth factors and cell-surface receptors, underscores its relevance in immunology and diagnostics.
Overall, NCL recombinant protein serves as a pivotal tool for dissecting nucleolin-related pathways and developing targeted therapies for cancers, viral diseases, and inflammatory disorders. Its versatility in both basic and applied research continues to drive innovations in biomedicine.
×
